
Cellectis SA is a biotechnology business based in the US. Cellectis shares (CLLS) are listed on the NASDAQ and all prices are listed in US Dollars. Cellectis employs 294 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Cellectis
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – CLLS – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Our top pick for
Beginners

Our top pick for
Building a portfolio

Our top pick for
Advanced traders

Cellectis stock price (NASDAQ: CLLS)
Use our graph to track the performance of CLLS stocks over time.Cellectis shares at a glance
Latest market close | $2.69 |
---|---|
52-week range | $2.30 - $15.84 |
50-day moving average | $3.31 |
200-day moving average | $6.75 |
Wall St. target price | $13.38 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-2.95 |
Buy Cellectis shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Cellectis stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Cellectis price performance over time
Historical closes compared with the close of $2.69 from 2022-07-01
1 week (2022-06-29) | -6.27% |
---|---|
1 month (2022-06-03) | -17.99% |
3 months (2022-04-06) | -40.22% |
6 months (2022-01-06) | -66.04% |
1 year (2021-07-06) | -81.90% |
---|---|
2 years (2020-07-06) | -85.88% |
3 years (2019-07-05) | 16.18 |
5 years (2017-07-05) | 25.5 |
Cellectis financials
Revenue TTM | $41.4 million |
---|---|
Gross profit TTM | $34.2 million |
Return on assets TTM | -23.35% |
Return on equity TTM | -58.65% |
Profit margin | 0% |
Book value | $4.20 |
Market capitalisation | $122.4 million |
TTM: trailing 12 months
Cellectis share dividends
We're not expecting Cellectis to pay a dividend over the next 12 months.
Cellectis share price volatility
Over the last 12 months, Cellectis's shares have ranged in value from as little as $2.3 up to $15.84. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cellectis's is 2.3017. This would suggest that Cellectis's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Cellectis overview
Cellectis S. A. , a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.
Cellectis in the news
Cellectis dévoile dans Nature Communications de nouvelles cellules CAR T universelles immuno-évasives dotées d'une persistance potentiellement améliorée
Cellectis Publishes Article in Nature Communications Unveiling Novel Immune-Evasive Universal Allogeneic CAR T-cells with Potential for Improved Persistence
Cellectis Publishes Article in Nature Communications Unveiling Novel Immune-Evasive Universal Allogeneic CAR T-cells with Potential for Improved Persistence
Frequently asked questions
What percentage of Cellectis is owned by institutions?Currently 29.353% of Cellectis shares are held by institutions. How many people work for Cellectis?
Latest data suggests 294 work at Cellectis. When does the fiscal year end for Cellectis?
Cellectis's fiscal year ends in December. Where is Cellectis based?
Cellectis's address is: 8, rue de la Croix Jarry, Paris, France, 75013 What is Cellectis's ISIN number?
Cellectis's international securities identification number is: US15117K1034 What is Cellectis's CUSIP number?
Cellectis's Committee on Uniform Securities Identification Procedures number is: 15117K103
More guides on Finder
-
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
-
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
-
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
-
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
-
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
-
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
-
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
-
How to buy Warrantee (WRNT) stock when it goes public
Everything we know about the Warrantee IPO, plus information on how to buy in.
-
How to buy Treasure Global (TGL) stock when it goes public
Everything we know about the Treasure Global IPO, plus information on how to buy in.
-
How to buy BIOLIFE4D (SAVU) stock when it goes public
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
Ask an Expert